CuraScientific (CuraScientific) FCF Margin % : -110.87% (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is CuraScientific FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CuraScientific's Free Cash Flow for the three months ended in Sep. 2023 was $-0.26 Mil. CuraScientific's Revenue for the three months ended in Sep. 2023 was $0.23 Mil. Therefore, CuraScientific's FCF Margin % for the quarter that ended in Sep. 2023 was -110.87%.

As of today, CuraScientific's current FCF Yield % is -80.90%.

The historical rank and industry rank for CuraScientific's FCF Margin % or its related term are showing as below:

CSTF' s FCF Margin % Range Over the Past 10 Years
Min: -791.18 Med: -721.67 Max: -45.45
Current: -45.45

During the past 3 years, the highest FCF Margin % of CuraScientific was -45.45%. The lowest was -791.18%. And the median was -721.67%.

CSTF's FCF Margin % is ranked worse than
84.13% of 1027 companies
in the Drug Manufacturers industry
Industry Median: -0.52 vs CSTF: -45.45

CuraScientific FCF Margin % Historical Data

The historical data trend for CuraScientific's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific FCF Margin % Chart

CuraScientific Annual Data

Trend

Dec20

Dec21

Dec22

FCF Margin %

-721.67

-651.16

-791.18

CuraScientific Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Margin %	Get a 7-Day Free Trial							-	-	-	-11.34	-110.87

Competitive Comparison of CuraScientific's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, CuraScientific's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CuraScientific's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CuraScientific's FCF Margin % distribution charts can be found below:

* The bar in red indicates where CuraScientific's FCF Margin % falls into.

CuraScientific FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

CuraScientific's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-0.269	/	0.034
	=	-791.18 %

CuraScientific's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-0.255	/	0.23
	=	-110.87 %

CuraScientific FCF Margin % Related Terms

Thank you for viewing the detailed overview of CuraScientific's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CuraScientific (CuraScientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236

Website

https://www.curascientificcorp.com

CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.

Executives

Paul Quentin Goyette	director	2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed	director, officer: Chief Executive Officer	333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen	director	C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette	director	13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez	director, officer: Chief Executive Officer	15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson	director, officer: Chief Operating Officer	19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

BOON to Announce Major Contract Start Date for DIOX+ $52M Revenue Stream

By Marketwired Marketwired • 02-03-2021

BOON Industries Debuts DiOx+ With $2M in Projected Revenue for Next 12 Months

By Marketwired Marketwired • 05-27-2020

BOON Industries Announces Initial Purchase Order With Major Beverage Company of 500,000 Units

By Marketwired Marketwired • 05-21-2020

Introducing Leaf of Faith

By Marketwired Marketwired • 03-26-2019

Boon Industries Moves Forward With New Technology & Intellectual Property

By Marketwired Marketwired • 05-19-2020